NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Mehdi Hamadani
Medical College of Wisconsin - Milwaukee / United States
Others
AD Scientific Index ID: 1389277
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Mehdi Hamadani's MOST POPULAR ARTICLES
1-)
Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromesBL Scott, MC Pasquini, BR Logan, J Wu, SM Devine, DL Porter, ...Journal of Clinical Oncology 35 (11), 1154, 20174752017
2-)
Current use of and trends in hematopoietic cell transplantation in the United StatesA D\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Souza, C Fretham, SJ Lee, M Arora, J Brunner, S Chhabra, S Devine, ...Biology of Blood and Marrow Transplantation 26 (8), e177-e182, 20203172020
3-)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trialNN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ...Nature medicine 26 (10), 1569-1575, 20203172020
4-)
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trialPF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ...The Lancet Oncology 22 (6), 790-800, 20213642021
5-)
Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual diseaseCS Hourigan, LW Dillon, G Gui, BR Logan, M Fei, J Ghannam, Y Li, ...Journal of Clinical Oncology 38 (12), 1273-1283, 20203452020
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept